Hengrui’s Licensing Surge Reflects a Deliberate Shift From Generics to Innovation
Jiangsu Hengrui Pharmaceuticals has moved from domestic heavyweight to a company multinational drugmakers now actively court. The scale of that shift became impossible to ignore in May, when Bristol Myers Squibb agreed to a $15.2 billion licensing package tied to 13 early-stage programs across oncology, hematology and immunology. Less than a year earlier, GSK had signed a separate deal with Hengrui covering 12 assets in respiratory, immunology, inflammation and oncology, with a total value of up to $12 billion. Those transactions did not happen by accident; they were the end result of a long R&D bet that began when the company was still known primarily for generics.
Hengrui’s rise is especially notable because it did not emerge from a start-up-style sprint. Founded in 1970 in Lianyungang, Jiangsu province, the company spent decades building an industrial base before pushing hard into innovative drug discovery. It launched its first mainland China IPO in 2000 and a second IPO in Hong Kong in 2025. Today it operates 15 R&D centers around the world and employs about 20,000 people. Scale alone does not create a pipeline, but scale does give a company the stamina to sustain one.
Platform Science, Early Development, and a Portfolio Built for Partnering
At the center of Hengrui’s current strategy is a simple premise: discover differentiated assets and move them efficiently through early development before handing some of that risk to larger global partners. Lianshan Zhang, Ph.D., the executive vice president responsible for the company’s innovation ecosystem, described 2027 as a “harvest season” for the pipeline and said Hengrui is still “seeking quality instead of just quantity.” The phrasing matters because it captures the company’s pivot away from broad output for its own sake and toward candidates with best-in-class potential.
The company now reports more than 400 clinical trials in progress and more than 100 new molecular entities under study across four main therapeutic areas: oncology; metabolic and cardiovascular diseases; immunological and respiratory diseases; and neuroscience. Specialized R&D platforms, including one powered by AI, have helped maintain an output of about 20 new molecular entities each year. On Citeline’s ranking, Hengrui is now the second-largest self-originated pharma pipeline in the world. That position is a consequence of sustained internal discovery capacity, not a one-off partnering windfall.
The scientific logic behind the model is straightforward. If a company can identify promising biology early, establish translational credibility, and de-risk first-in-human or phase 1-ready assets, it becomes far more attractive to multinational partners seeking both speed and optionality. Hengrui’s own framing of its value proposition to BMS makes that explicit: its discovery engine, platform technologies, and efficient early-stage development expertise enable the advancement of a broad portfolio of high-value programs. In a crowded global market, early discipline is a commercial asset.
Why BMS and GSK Paid for Hengrui’s Early-Stage Engine
The BMS agreement spans 13 programs and includes five assets the two companies will co-discover and co-develop. The GSK deal similarly centered on early-stage innovation, and in both cases Hengrui retained responsibility for early clinical development. That arrangement says as much about the Chinese company’s operating model as it does about the appetite of Western pharmaceutical firms for Chinese-origin innovation.
Hengrui did not arrive at this point by chasing me-too molecules. For the past five years, Zhang said, the company has focused on differentiated candidates with best-in-class potential. In oncology and immunology especially, the value of that approach is obvious: crowded categories penalize incrementalism and reward assets that can separate themselves on potency, selectivity, dosing convenience, or a more favorable safety profile. The market has become unforgiving toward modest differentiation.
One sentence captures the abrupt commercial change. Hengrui is no longer simply exporting ideas; it is exporting development capability.
New Drug Sales Now Drive the Majority of Revenue
The transformation is visible in the company’s own numbers. In the first six months of 2026, revenue from new drugs approved in China reached $1.3 billion, representing 63% of total drug revenue. That is a major milestone for a company whose legacy business once rested on generics. The approved portfolio now includes trastuzumab rezetecan, a HER2 antibody-drug conjugate approved in China for HER2-mutant non-small cell lung cancer and HER2-positive breast and colorectal cancers, along with dalpiciclib, an oral CDK4/6 inhibitor for HR-positive, HER2-negative breast cancer, and fuzuloparib, a PARP1/2 inhibitor used mainly for ovarian cancer.
The list does not stop there. Hengrui also markets henagliflozin, an SGLT2 inhibitor for type 2 diabetes, and recaticimab, an anti-PCSK9 monoclonal antibody for lowering LDL cholesterol. In practical terms, that means the company has already proven it can move beyond discovery rhetoric and into commercial execution across multiple disease areas. Oncology supplies one growth engine, but not the only one.
Metabolic Disease Has Become Hengrui’s Second Growth Engine
Zhang identified metabolism and cardiovascular disease as another major pillar, and the company is leaning hard into obesity and diabetes therapies. Hengrui says it now has the most comprehensive and differentiated pipeline in diabetes and weight management, with a mix of development-stage and marketed assets. That category matters because GLP-1 biology has redefined the commercial and scientific expectations for metabolic drugs, and combination incretin strategies are now where many of the most ambitious bets sit.
In September, Novo agreed to pay up to $2.6 billion for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist designed for once-weekly oral dosing, including a $300 million upfront payment. Oral delivery remains one of the most important competitive battlegrounds in obesity pharmacology because it widens the path to chronic use and may improve patient acceptance compared with injectable regimens. A dual GLP-1/GIP approach also reflects the field’s push to amplify appetite suppression and metabolic effects through complementary incretin signaling.
The partnership also signaled external validation of Hengrui’s discovery engine. Novo’s chief scientific officer, Martin Holst Lange, M.D., Ph.D., praised the company’s “proven track record of discovering and advancing innovative therapies.” In drug development, partner confidence often follows reproducible execution rather than promises.
A Long View on China’s Biopharma Maturation
Zhang’s own career path helps explain the company’s evolution. After spending most of his professional life in the United States, working in peptide therapeutics and drug development at Eli Lilly and at GLP-1 pioneer Marcadia Biotech, he returned to China in 2010 to lead global R&D at Hengrui. The assignment was ambitious: reshape the company’s research strategy around innovation. More than a decade later, the payoff is visible in pipeline breadth, deal volume, and revenue mix.
Hengrui’s story also reflects a broader shift in Chinese biopharma, where local companies are increasingly moving from manufacturing strength into global innovation partnerships. Still, the company’s own profile remains distinctive because it combined longevity, internal platform building, and disciplined early development long before the recent licensing boom made those qualities fashionable. The result is a company that can support dozens of clinical programs while negotiating at a level once reserved for long-established Western peers.
What remains unresolved is the same question facing every deep pipeline: how many of these assets will translate from early promise to durable clinical and commercial value. The 2027 “harvest season” Zhang described will answer part of that, but the real test will come as more of the 400-plus trials generate human efficacy and safety data. Until then, Hengrui’s edge rests on a simple advantage: it has become one of the few Chinese drugmakers able to pair discovery scale with credible development discipline.